EIKNEikon Therapeutics, Inc.
$7.48
$7.48
$7.3152 weeks$16.26
The financials
Eikon Therapeutics, Inc. by the numbers
Eikon Therapeutics, Inc. (EIKN) reported revenue of $5.0M in Q2 2026 (quarter ended Jun 30, 2026), up 59% from the same quarter a year earlier. That came with net loss of $88M. The next results filing is expected around Nov 12, 2026, a quarter after the last one.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $5.0M | $3.2M | +59% |
| Operating income | −$93M | −$71M | n/a |
| Net income | −$88M | −$68M | n/a |
| Diluted EPS | −$1.63 | −$26.91 | n/a |
Biotechnology
The closest names by size in the same industry